{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:04:51Z","timestamp":1777878291657,"version":"3.51.4"},"reference-count":25,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Despite improvements in hemophilia care, challenges remain, including treatment burden and impaired quality of life. Gene therapy may overcome these. However, its introduction presents a challenge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To outline a function-based gene therapy working model describing critical milestones associated with gene therapy handling, administration, and follow-up to facilitate and implement an effective infrastructure for gene therapy introduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Literature review and consensus discussion among Hemophilia Comprehensive Care centers (HCCCs) in the Nordic region.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Representatives from six HCCCs sought to pinpoint milestones and key stakeholders for site readiness at the pre-, peri-, and post-infusion stages, including authority and genetically modified organism (GMO) product requirements, awareness, medical eligibility, logistics and product handling for infusion, laboratory monitoring, and follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A gene therapy transit map was developed with key stakeholders identified. The approach to prepare the vector will differ between the Nordic centers, but the contracted pharmacy unit will be a key stakeholder. Therefore, a pharmacy checklist for the implementation of gene therapy was developed. For the future, Advanced Therapy Medicinal Product centers will also be implemented. Patients\u2019 expectations, commitments, and concerns need to be addressed repeatedly and education of patients and the expanded health-care professionals team will be the key to successful and optimal clinical management. Eligibility testing according to the product\u2019s summary of product characteristics and frequent follow-up and monitoring post-infusion according to the World Federation of Hemophilia chart will be crucial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The approach to deliver gene therapy in the Nordic region will differ partly between the hemophilia centers, but the defined road map with checklists for the implementation of this advanced therapy will be applicable to all. The map may also serve as a platform for the use of future GMO product options both within and outside the area of hemophilia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406207231202306","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T07:43:12Z","timestamp":1697528592000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Infrastructural considerations of implementing gene therapy for hemophilia in the Nordic context"],"prefix":"10.1177","volume":"14","author":[{"given":"Jan","family":"Astermark","sequence":"first","affiliation":[{"name":"Department of Translational Medicine, Lund University, Malm\u00f6, Sweden"},{"name":"Department of Hematology, Oncology and Radiation Physics, Sk\u00e5ne University Hospital, Jan Waldenstr\u00f6ms gata 14, Malm\u00f6, SE-205 02, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fariba","family":"Baghaei","sequence":"additional","affiliation":[{"name":"Department of Medicine, Region V\u00e4stra G\u00f6taland, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Strandberg","sequence":"additional","affiliation":[{"name":"Division of Laboratory Medicine, Department of Clinical Chemistry and Pharmacology, Coagulation, University and Regional Laboratories Region Sk\u00e5ne, Malm\u00f6, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra Gabric","family":"Toplican","sequence":"additional","affiliation":[{"name":"Radiopharmacy Unit, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maj Friberg","family":"Birkedal","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology\/Oncology, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma Engman","family":"Grahn","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Radiation Physics, Sk\u00e5ne University Hospital, Malm\u00f6, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotta","family":"Hansson","sequence":"additional","affiliation":[{"name":"BioMarin (Europe) Limited, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Kampmann","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Elina","family":"Lehtinen","sequence":"additional","affiliation":[{"name":"Coagulation Disorders Unit, Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinga","family":"T\u00e4ckstr\u00f6m","sequence":"additional","affiliation":[{"name":"BioMarin (Europe) Limited, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e5l Andre","family":"Holme","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oslo University Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Magnusson","sequence":"additional","affiliation":[{"name":"Coagulation Unit, Department of Hematology, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Clinical Chemistry and Blood Coagulation Research, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"key":"bibr1-20406207231202306","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02909.x"},{"key":"bibr2-20406207231202306","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13769"},{"key":"bibr3-20406207231202306","unstructured":"Windyga J, Tran H, Fujii T, et al. Real-world unmet needs of patients with haemophilia A\/B with or without inhibitors: historical haemophilia characteristics from patients entering a non-interventional study [abstract]. ISTH 2022 congress. Abstract PB1163, https:\/\/abstracts.isth.org\/abstract\/real-world-unmet-needs-of-patients-with-haemophilia-a-b-with-or-without-inhibitors-historical-haemophilia-characteristics-from-patients-entering-a-non-interventional-study\/ (2022, accessed 18 May 2023)."},{"key":"bibr4-20406207231202306","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2002842"},{"key":"bibr5-20406207231202306","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908490"},{"key":"bibr6-20406207231202306","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708538"},{"key":"bibr7-20406207231202306","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S355627"},{"key":"bibr8-20406207231202306","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14709"},{"key":"bibr9-20406207231202306","doi-asserted-by":"publisher","DOI":"10.1055\/a-1957-4477"},{"key":"bibr10-20406207231202306","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14420"},{"key":"bibr11-20406207231202306","doi-asserted-by":"publisher","DOI":"10.4037\/ajcc2015455"},{"key":"bibr12-20406207231202306","unstructured":"European Association for Haemophilia and Allied Disorders (EAHAD). European guidelines for the certification of Haemophilia Centres, https:\/\/www.eahad.org\/wp-content\/uploads\/2023\/02\/EuhanetEuropean_guidelines_for_the_certification_of_Haemophilia_Centres_NEW.pdf (2013, accessed 18 May 2023)."},{"key":"bibr13-20406207231202306","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810228"},{"key":"bibr14-20406207231202306","unstructured":"World Health Organization. Laboratory biosafety manual, 4th ed., https:\/\/www.who.int\/publications\/i\/item\/9789240011311 (2020, accessed 18 May 2023)."},{"key":"bibr15-20406207231202306","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100759"},{"key":"bibr16-20406207231202306","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14572"},{"key":"bibr17-20406207231202306","first-page":"1","volume":"2","author":"Woollard L","year":"2021","journal-title":"Ther Adv Rare Dis"},{"key":"bibr18-20406207231202306","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13504"},{"key":"bibr19-20406207231202306","doi-asserted-by":"publisher","DOI":"10.17225\/jhp00176"},{"key":"bibr20-20406207231202306","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.11.014"},{"key":"bibr21-20406207231202306","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000540"},{"key":"bibr22-20406207231202306","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211644"},{"key":"bibr23-20406207231202306","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13976"},{"key":"bibr24-20406207231202306","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005683"},{"key":"bibr25-20406207231202306","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2019.0010"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207231202306","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207231202306","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207231202306","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:16:49Z","timestamp":1777591009000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207231202306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":25,"alternative-id":["10.1177\/20406207231202306"],"URL":"https:\/\/doi.org\/10.1177\/20406207231202306","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"20406207231202306"}}